{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T03:47:58Z","timestamp":1763092078887},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00277-008-0531-7","type":"journal-article","created":{"date-parts":[[2008,7,15]],"date-time":"2008-07-15T12:16:48Z","timestamp":1216124208000},"page":"1-10","source":"Crossref","is-referenced-by-count":24,"title":["Long-term management of thrombocytosis in essential thrombocythaemia"],"prefix":"10.1007","volume":"88","author":[{"given":"Gunnar","family":"Birgeg\u00e5rd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,16]]},"reference":[{"key":"531_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-2-3","volume":"2","author":"JB Briere","year":"2007","unstructured":"Briere JB (2007) Essential thrombocythemia. Orphanet J Rare Dis 2:3 doi: 10.1186\/1750-1172-2-3","journal-title":"Orphanet J Rare Dis"},{"key":"531_CR2","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","volume":"65","author":"MK Jensen","year":"2000","unstructured":"Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65:132\u2013139 doi: 10.1034\/j.1600-0609.2000.90236.x","journal-title":"Eur J Haematol"},{"key":"531_CR3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953 doi: 10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"key":"531_CR4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.5858\/2006-130-1144-ET","volume":"130","author":"S Sanchez","year":"2006","unstructured":"Sanchez S, Ewton A (2006) Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med 130:1144\u20131150","journal-title":"Arch Pathol Lab Med"},{"key":"531_CR5","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.2165\/00003495-200666170-00003","volume":"66","author":"EI Penninga","year":"2006","unstructured":"Penninga EI, Bjerrum OW (2006) Polycythaemia vera and essential thrombocythaemia: current treatment strategies. Drugs 66:2173\u20132187 doi: 10.2165\/00003495-200666170-00003","journal-title":"Drugs"},{"key":"531_CR6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","volume":"93","author":"CN Harrison","year":"1999","unstructured":"Harrison CN, Gale RE, Machin SJ, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417\u2013424","journal-title":"Blood"},{"key":"531_CR7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00277-004-0864-9","volume":"83","author":"M Griesshammer","year":"2004","unstructured":"Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H et al (2004) PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 83:364\u2013370 doi: 10.1007\/s00277-004-0864-9","journal-title":"Ann Hematol"},{"key":"531_CR8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V100.2.714","volume":"100","author":"L Teofili","year":"2002","unstructured":"Teofili L, Pierconti F, Di Febo A, Maggiano N, Vianelli N, Ascani S et al (2002) The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 100:714\u2013717 doi: 10.1182\/blood.V100.2.714","journal-title":"Blood"},{"key":"531_CR9","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","volume":"102","author":"R Kralovics","year":"2003","unstructured":"Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP et al (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102:1869\u20131871 doi: 10.1182\/blood-2003-03-0744","journal-title":"Blood"},{"key":"531_CR10","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and JAK2 mutation status. Blood 109:2310\u20132313 doi: 10.1182\/blood-2006-09-046342","journal-title":"Blood"},{"key":"531_CR11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2141.2005.05543.x","volume":"130","author":"CN Harrison","year":"2005","unstructured":"Harrison CN (2005) Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 130:153\u2013165 doi: 10.1111\/j.1365-2141.2005.05543.x","journal-title":"Br J Haematol"},{"key":"531_CR12","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092\u20131097 doi: 10.1182\/blood-2007-04-083501","journal-title":"Blood"},{"key":"531_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000101708","volume":"74","author":"J Thiele","year":"2007","unstructured":"Thiele J, Kvasnicka HM (2007) Myelofibrosis\u2014what\u2019s in a name? Consensus on definition and EUMNET grading. Pathobiology 74:89\u201396 doi: 10.1159\/000101708","journal-title":"Pathobiology"},{"key":"531_CR14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-2006-942757","volume":"32","author":"HM Kvasnicka","year":"2006","unstructured":"Kvasnicka HM, Thiele J (2006) The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 32:362\u2013371 doi: 10.1055\/s-2006-942757","journal-title":"Semin Thromb Hemost"},{"key":"531_CR15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.10116","volume":"70","author":"J Thiele","year":"2002","unstructured":"Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V (2002) Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol 70:283\u2013291 doi: 10.1002\/ajh.10116","journal-title":"Am J Hematol"},{"key":"531_CR16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0344-0338(11)80081-6","volume":"189","author":"T Buhr","year":"1993","unstructured":"Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 189:121\u2013132","journal-title":"Pathol Res Pract"},{"key":"531_CR17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000083452","volume":"113","author":"A Kreft","year":"2005","unstructured":"Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ (2005) The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 113:137\u2013143 doi: 10.1159\/000083452","journal-title":"Acta Haematol"},{"key":"531_CR18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL et al (2008) Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111:60\u201370 doi: 10.1182\/blood-2007-05-091850","journal-title":"Blood"},{"key":"531_CR19","first-page":"E25","volume":"10","author":"JA Colwell","year":"2006","unstructured":"Colwell JA (2006) Aspirin for the primary prevention of cardiovascular events. Timely Top Med Cardiovasc Dis 10:E25","journal-title":"Timely Top Med Cardiovasc Dis"},{"key":"531_CR20","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.V80.8.1965.1965","volume":"80","author":"R Landolfi","year":"1992","unstructured":"Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B et al (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965\u20131971","journal-title":"Blood"},{"key":"531_CR21","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","volume":"74","author":"B Rocca","year":"1995","unstructured":"Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C et al (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 74:1225\u20131230","journal-title":"Thromb Haemost"},{"key":"531_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/107602969900500210","volume":"5","author":"ML Randi","year":"1999","unstructured":"Randi ML, Rossi C, Fabris F, Menapace L, Girolami A (1999) Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb Hemost 5:131\u2013135 doi: 10.1177\/107602969900500210","journal-title":"Clin Appl Thromb Hemost"},{"key":"531_CR23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","volume":"97","author":"PJ Genderen van","year":"1997","unstructured":"van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 97:179\u2013184 doi: 10.1046\/j.1365-2141.1997.d01-2127.x","journal-title":"Br J Haematol"},{"key":"531_CR24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.43.6.1107","volume":"43","author":"JJ Michiels","year":"1993","unstructured":"Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH (1993) Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107\u20131110","journal-title":"Neurology"},{"key":"531_CR25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0038-1653752","volume":"73","author":"PJ Genderen van","year":"1995","unstructured":"van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 73:210\u2013214","journal-title":"Thromb Haemost"},{"key":"531_CR26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114\u2013124 doi: 10.1056\/NEJMoa035572","journal-title":"N Engl J Med"},{"key":"531_CR27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2007-996111","volume":"23","author":"M Griesshammer","year":"1997","unstructured":"Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ (1997) Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Hemost 23:371\u2013377","journal-title":"Semin Thromb Hemost"},{"key":"531_CR28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1040-8428(98)00032-8","volume":"29","author":"P Navarra","year":"1999","unstructured":"Navarra P, Preziosi P (1999) Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29:249\u2013255 doi: 10.1016\/S1040-8428(98)00032-8","journal-title":"Crit Rev Oncol Hematol"},{"key":"531_CR29","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","volume":"332","author":"S Cortelazzo","year":"1995","unstructured":"Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132\u20131136 doi: 10.1056\/NEJM199504273321704","journal-title":"N Engl J Med"},{"key":"531_CR30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33\u201345 doi: 10.1056\/NEJMoa043800","journal-title":"N Engl J Med"},{"key":"531_CR31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1600-0609.1988.tb00212.x","volume":"41","author":"E Lofvenberg","year":"1988","unstructured":"Lofvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375\u2013381","journal-title":"Eur J Haematol"},{"key":"531_CR32","first-page":"261","volume":"90","author":"ML Randi","year":"2005","unstructured":"Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F (2005) Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 90:261\u2013262","journal-title":"Haematologica"},{"key":"531_CR33","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/blood-2003-01-0135","volume":"101","author":"G Finazzi","year":"2003","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 101:3749 doi: 10.1182\/blood-2003-01-0135","journal-title":"Blood"},{"key":"531_CR34","doi-asserted-by":"crossref","unstructured":"Gisslinger H, Kralovics R, Gotic M, Holowiecki J, Penka M, Widmann R et al (2007) Non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed patients with essential thrombocythaemia: the ANAHYDRET study. In: 49th Annual Society of Hematology Annual Meeting, Atlanta, USA, 8\u201311 December","DOI":"10.1182\/blood.V110.11.3547.3547"},{"key":"531_CR35","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","volume":"89","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD, The French Polycythemia Study Group (1997) Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65\u00a0years of age. Blood 89:2319\u20132327","journal-title":"Blood"},{"key":"531_CR36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","volume":"110","author":"G Finazzi","year":"2000","unstructured":"Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 110:577\u2013583 doi: 10.1046\/j.1365-2141.2000.02188.x","journal-title":"Br J Haematol"},{"key":"531_CR37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","volume":"91","author":"Y Sterkers","year":"1998","unstructured":"Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616\u2013622","journal-title":"Blood"},{"key":"531_CR38","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/j.1365-2141.2002.3346_1.x","volume":"116","author":"ML Randi","year":"2002","unstructured":"Randi ML, Fabris F, Girolami A (2002) Second malignancies in patients with essential thrombocythaemia. Br J Haematol 116:923\u2013924 doi: 10.1111\/j.1365-2141.2002.3346_1.x","journal-title":"Br J Haematol"},{"key":"531_CR39","first-page":"29","volume":"34","author":"S Murphy","year":"1997","unstructured":"Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29\u201339","journal-title":"Semin Hematol"},{"key":"531_CR40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00003088-199834050-00002","volume":"34","author":"PR Gwilt","year":"1998","unstructured":"Gwilt PR, Tracewell WG (1998) Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34:347\u2013358 doi: 10.2165\/00003088-199834050-00002","journal-title":"Clin Pharmacokinet"},{"key":"531_CR41","first-page":"1071","volume":"20","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graff A (2005) Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 20:1071\u20131076","journal-title":"Histol Histopathol"},{"key":"531_CR42","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1038\/sj.leu.2402638","volume":"16","author":"P Bernasconi","year":"2002","unstructured":"Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F et al (2002) Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 16:2078\u20132083 doi: 10.1038\/sj.leu.2402638","journal-title":"Leukemia"},{"key":"531_CR43","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","volume":"165","author":"CS Chim","year":"2005","unstructured":"Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG et al (2005) Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165:2651\u20132658 doi: 10.1001\/archinte.165.22.2651","journal-title":"Arch Intern Med"},{"key":"531_CR44","first-page":"17","volume":"34","author":"SM Fruchtman","year":"1997","unstructured":"Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR (1997) From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17\u201323","journal-title":"Semin Hematol"},{"key":"531_CR45","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","volume":"32","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P (2006) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:417\u2013421 doi: 10.1055\/s-2006-942762","journal-title":"Semin Thromb Hemost"},{"key":"531_CR46","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","volume":"90","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD (1997) Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65\u00a0years. Blood 90:3370\u20133377","journal-title":"Blood"},{"key":"531_CR47","first-page":"172","volume":"13","author":"MR Stevens","year":"1999","unstructured":"Stevens MR (1999) Hydroxyurea: an overview. J Biol Regul Homeost Agents 13:172\u2013175","journal-title":"J Biol Regul Homeost Agents"},{"key":"531_CR48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/106002809502900205","volume":"29","author":"IS Lossos","year":"1995","unstructured":"Lossos IS, Matzner Y (1995) Hydroxyurea-induced fever: case report and review of the literature. Ann Pharmacother 29:132\u2013133","journal-title":"Ann Pharmacother"},{"key":"531_CR49","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000041071","volume":"104","author":"A Braester","year":"2000","unstructured":"Braester A, Quitt M (2000) Hydroxyurea as a cause of drug fever. Acta Haematol 104:50\u201351 doi: 10.1159\/000041071","journal-title":"Acta Haematol"},{"key":"531_CR50","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1600-0609.1999.tb01917.x","volume":"62","author":"O Lannemyr","year":"1999","unstructured":"Lannemyr O, Kutti J (1999) Hydroxyurea as a cause of drug fever in essential thrombocythaemia. Eur J Haematol 62:354\u2013355","journal-title":"Eur J Haematol"},{"key":"531_CR51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archderm.1975.01630140041002","volume":"111","author":"BJ Kennedy","year":"1975","unstructured":"Kennedy BJ, Smith LR, Goltz RW (1975) Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111:183\u2013187 doi: 10.1001\/archderm.111.2.183","journal-title":"Arch Dermatol"},{"key":"531_CR52","first-page":"262","volume":"12","author":"G Dumont-Wallon","year":"2006","unstructured":"Dumont-Wallon G, Milpied-Homsi B, Morineau N (2006) Effets secondaires cutan\u00e9omuqueux de l\u2019hydroxyur\u00e9e: \u00e9tude prospective sur 27 patients. Hematologie 12:262\u2013266","journal-title":"Hematologie"},{"key":"531_CR53","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/09546630600780494","volume":"17","author":"E Zaccaria","year":"2006","unstructured":"Zaccaria E, Cozzani E, Parodi A (2006) Secondary cutaneous effects of hydroxyurea: possible pathogenetic mechanisms. J Dermatolog Treat 17:176\u2013178 doi: 10.1080\/09546630600780494","journal-title":"J Dermatolog Treat"},{"key":"531_CR54","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4065\/73.10.961","volume":"73","author":"PJ Best","year":"1998","unstructured":"Best PJ, Petitt RM (1998) Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin Proc 73:961\u2013963","journal-title":"Mayo Clin Proc"},{"key":"531_CR55","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10428199909145710","volume":"35","author":"F Ravandi-Kashani","year":"1999","unstructured":"Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O\u2019Brien S, Markowitz A et al (1999) Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35:109\u2013118 doi: 10.3109\/10428199909145710","journal-title":"Leuk Lymphoma"},{"key":"531_CR56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/shem.2003.50031","volume":"40","author":"HS Gilbert","year":"2003","unstructured":"Gilbert HS (2003) Modern treatment strategies in polycythemia vera. Semin Hematol 40:26\u201329","journal-title":"Semin Hematol"},{"key":"531_CR57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMe058093","volume":"353","author":"T Barbui","year":"2005","unstructured":"Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. N Engl J Med 353:85\u201386 doi: 10.1056\/NEJMe058093","journal-title":"N Engl J Med"},{"key":"531_CR58","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/10428190400029817","volume":"46","author":"D Dingli","year":"2005","unstructured":"Dingli D, Tefferi A (2005) A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 46:641\u2013650 doi: 10.1080\/10428190400029817","journal-title":"Leuk Lymphoma"},{"key":"531_CR59","first-page":"215","volume":"89","author":"T Barbui","year":"2004","unstructured":"Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215\u2013232","journal-title":"Haematologica"},{"key":"531_CR60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/09537100400020179","volume":"16","author":"ML Randi","year":"2005","unstructured":"Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F (2005) Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16:181\u2013184 doi: 10.1080\/09537100400020179","journal-title":"Platelets"},{"key":"531_CR61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.leu.2404473","volume":"21","author":"G Barosi","year":"2007","unstructured":"Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G et al (2007) A unified definition of clinical resistance\/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia 21:277\u2013280 doi: 10.1038\/sj.leu.2404473","journal-title":"Leukemia"},{"key":"531_CR62","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/sj.leu.2404180","volume":"20","author":"Y Hong","year":"2006","unstructured":"Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD (2006) Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20:1117\u20131122 doi: 10.1038\/sj.leu.2404180","journal-title":"Leukemia"},{"key":"531_CR63","first-page":"520","volume":"89","author":"G Birgegard","year":"2004","unstructured":"Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B et al (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89:520\u2013527","journal-title":"Haematologica"},{"key":"531_CR64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","volume":"29","author":"SM Fruchtman","year":"2005","unstructured":"Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A (2005) Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 29:481\u2013491 doi: 10.1016\/j.leukres.2004.10.002","journal-title":"Leuk Res"},{"key":"531_CR65","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","volume":"101","author":"M Steurer","year":"2004","unstructured":"Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E et al (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101:2239\u20132246 doi: 10.1002\/cncr.20646","journal-title":"Cancer"},{"key":"531_CR66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2257.2004.00637.x","volume":"26","author":"E Penninga","year":"2004","unstructured":"Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ et al (2004) Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 26:335\u2013340 doi: 10.1111\/j.1365-2257.2004.00637.x","journal-title":"Clin Lab Haematol"},{"key":"531_CR67","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V97.4.863","volume":"97","author":"EC Storen","year":"2001","unstructured":"Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863\u2013866 doi: 10.1182\/blood.V97.4.863","journal-title":"Blood"},{"key":"531_CR68","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/107602960000600307","volume":"6","author":"MS Laguna","year":"2000","unstructured":"Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC (2000) Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 6:157\u2013161 doi: 10.1177\/107602960000600307","journal-title":"Clin Appl Thromb Hemost"},{"key":"531_CR69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1445-5994.1999.tb01585.x","volume":"29","author":"AK Mills","year":"1999","unstructured":"Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC et al (1999) Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 29:29\u201335","journal-title":"Aust N Z J Med"},{"key":"531_CR70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0609.1998.tb01064.x","volume":"61","author":"PE Petrides","year":"1998","unstructured":"Petrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 61:71\u201376","journal-title":"Eur J Haematol"},{"key":"531_CR71","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(92)90017-6","volume":"92","author":"Anagrelide Study Group","year":"1992","unstructured":"Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 92:69\u201376 doi: 10.1016\/0002-9343(92)90017-6","journal-title":"Am J Med"},{"key":"531_CR72","first-page":"51","volume":"34","author":"RM Petitt","year":"1997","unstructured":"Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51\u201354","journal-title":"Semin Hematol"},{"key":"531_CR73","first-page":"315","volume":"77","author":"MG Mazzucconi","year":"1992","unstructured":"Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F (1992) Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 77:315\u2013317","journal-title":"Haematologica"},{"key":"531_CR74","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1517\/14656566.5.8.1781","volume":"5","author":"PE Petrides","year":"2004","unstructured":"Petrides PE (2004) Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 5:1781\u20131798 doi: 10.1517\/14656566.5.8.1781","journal-title":"Expert Opin Pharmacother"},{"key":"531_CR75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.02.006","volume":"41","author":"T Barbui","year":"2004","unstructured":"Barbui T (2004) The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both. Semin Hematol 41:15\u201317 doi: 10.1053\/j.seminhematol.2004.02.006","journal-title":"Semin Hematol"},{"key":"531_CR76","first-page":"1306","volume":"89","author":"MG Mazzucconi","year":"2004","unstructured":"Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R et al (2004) A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89:1306\u20131313","journal-title":"Haematologica"},{"key":"531_CR77","first-page":"320","volume":"5","author":"A Zomas","year":"2002","unstructured":"Zomas A, Marinakis T, Grigoraki V, Gortzolidis G, Arseni P, Skandali A et al (2002) The use anagrelide for control of thrombocytosis in Greek patients with myeloproliferative disorders. Haem 5:320\u2013325","journal-title":"Haem"},{"key":"531_CR78","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1055\/s-2006-939437","volume":"32","author":"G Birgegard","year":"2006","unstructured":"Birgegard G (2006) Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 32:260\u2013266 doi: 10.1055\/s-2006-939437","journal-title":"Semin Thromb Hemost"},{"key":"531_CR79","first-page":"989","volume":"15","author":"HS Gilbert","year":"2001","unstructured":"Gilbert HS (2001) Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. Oncology 15:989\u2013996 Williston Park","journal-title":"Oncology"},{"key":"531_CR80","first-page":"1445","volume":"112","author":"G Mazur","year":"2004","unstructured":"Mazur G, Wrobel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J et al (2004) Anagrelide in the treatment of thrombocythemia essential (ET). Pol Arch Med Wewn 112:1445\u20131450","journal-title":"Pol Arch Med Wewn"},{"key":"531_CR81","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0950-3536(98)80038-3","volume":"11","author":"A Tefferi","year":"1998","unstructured":"Tefferi A, Silverstein MN (1998) Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol 11:769\u2013785 doi: 10.1016\/S0950-3536(98)80038-3","journal-title":"Baillieres Clin Haematol"},{"key":"531_CR82","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.V77.10.2103.2103","volume":"77","author":"H Wadenvik","year":"1991","unstructured":"Wadenvik H, Kutti J, Ridell B, Revesz P, Jacobsson S, Magnusson B et al (1991) The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77:2103\u20132108","journal-title":"Blood"},{"key":"531_CR83","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","volume":"108","author":"JJ Kiladjian","year":"2006","unstructured":"Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037\u20132040 doi: 10.1182\/blood-2006-03-009860","journal-title":"Blood"},{"key":"531_CR84","first-page":"1281","volume":"91","author":"J Samuelsson","year":"2006","unstructured":"Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P, Bjorkholm M, Pahl HL (2006) Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 91:1281\u20131282","journal-title":"Haematologica"},{"key":"531_CR85","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","volume":"107","author":"AV Jones","year":"2006","unstructured":"Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339\u20133341 doi: 10.1182\/blood-2005-09\u20133917","journal-title":"Blood"},{"key":"531_CR86","first-page":"420","volume":"143","author":"HL Seewann","year":"1993","unstructured":"Seewann HL (1993) Interferon therapy in essential thrombocythemia. Wien Med Wochenschr 143:420\u2013424","journal-title":"Wien Med Wochenschr"},{"issue":"Suppl 4","key":"531_CR87","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/0277-5379(91)90578-2","volume":"27","author":"X Yataganas","year":"1991","unstructured":"Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F, Tsekoura C et al (1991) alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 27(Suppl 4):S69\u2013S71","journal-title":"Eur J Cancer"},{"key":"531_CR88","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","volume":"106","author":"J Samuelsson","year":"2006","unstructured":"Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M et al (2006) A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106:2397\u20132405 doi: 10.1002\/cncr.21900","journal-title":"Cancer"},{"issue":"Suppl 1","key":"531_CR89","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/10428199609074371","volume":"22","author":"E Lengfelder","year":"1996","unstructured":"Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22(Suppl 1):135\u2013142 doi: 10.3109\/10428199609074371","journal-title":"Leuk Lymphoma"},{"key":"531_CR90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","volume":"79","author":"E Lengfelder","year":"2000","unstructured":"Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79:103\u2013109 doi: 10.1007\/s002770050563","journal-title":"Ann Hematol"},{"key":"531_CR91","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/sonc.2002.33757","volume":"29","author":"HS Gilbert","year":"2002","unstructured":"Gilbert HS (2002) Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 29:22\u201327","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"531_CR92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2141.1991.tb08118.x","volume":"79","author":"H Gisslinger","year":"1991","unstructured":"Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H (1991) Interferon in essential thrombocythaemia. Br J Haematol 79(Suppl 1):42\u201347 doi: 10.1111\/j.1365-2141.1991.tb08118.x","journal-title":"Br J Haematol"},{"key":"531_CR93","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/1042819021000029948","volume":"44","author":"M \u00c7abuk","year":"2003","unstructured":"\u00c7abuk M, Pirildar T, Ceylan C, Koral L, Kirmaz C, Kiliccioglu B et al (2003) Arthritis induced by interferon-alpha therapy in a patient with essential thrombocythemia. Leuk Lymphoma 44:377\u2013378 doi: 10.1080\/1042819021000029948","journal-title":"Leuk Lymphoma"},{"key":"531_CR94","first-page":"177","volume":"37","author":"L Salvo De","year":"1996","unstructured":"De Salvo L, Plumacher Z, Gomez O, Weir-Medina J, Paz L, Salas D (1996) Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia. Invest Clin 37:177\u2013181","journal-title":"Invest Clin"},{"key":"531_CR95","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00041327-200312000-00003","volume":"23","author":"Y Vardizer","year":"2003","unstructured":"Vardizer Y, Linhart Y, Loewenstein A, Garzozi H, Mazawi N, Kesler A (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256\u2013259 doi: 10.1097\/00041327-200312000-00003","journal-title":"J Neuroophthalmol"},{"key":"531_CR96","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/028418602317314064","volume":"41","author":"M Merup","year":"2002","unstructured":"Merup M, Aberg W, Lofvenberg E, Svensson E, Engman K, Paul C et al (2002) Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 41:50\u201355 doi: 10.1080\/028418602317314064","journal-title":"Acta Oncol"},{"key":"531_CR97","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230701333038","volume":"19","author":"P Malek-Ahmadi","year":"2007","unstructured":"Malek-Ahmadi P, Hilsabeck RC (2007) Neuropsychiatric complications of interferons: classification, neurochemical bases, and management. Ann Clin Psychiatry 19:113\u2013123 doi: 10.1080\/10401230701333038","journal-title":"Ann Clin Psychiatry"},{"key":"531_CR98","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1345\/aph.10172","volume":"35","author":"P Malek-Ahmadi","year":"2001","unstructured":"Malek-Ahmadi P (2001) Mood disorders associated with interferon treatment: theoretical and practical considerations. Ann Pharmacother 35:489\u2013495 doi: 10.1345\/aph.10172","journal-title":"Ann Pharmacother"},{"key":"531_CR99","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-2006-942761","volume":"32","author":"A Quintas-Cardama","year":"2006","unstructured":"Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S (2006) Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32:409\u2013416 doi: 10.1055\/s-2006-942761","journal-title":"Semin Thromb Hemost"},{"key":"531_CR100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00280-002-0533-4","volume":"51","author":"Y Alvarado","year":"2003","unstructured":"Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z et al (2003) Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 51:81\u201386 doi: 10.1007\/s00280-002-0533-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"531_CR101","first-page":"1333","volume":"90","author":"C Langer","year":"2005","unstructured":"Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H et al (2005) Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study. Haematologica 90:1333\u20131338","journal-title":"Haematologica"},{"key":"531_CR102","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.23018","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A et al (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a Phase 2 study. Cancer 110:2012\u20132018 doi: 10.1002\/cncr.23018","journal-title":"Cancer"},{"key":"531_CR103","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1055\/s-2006-942758","volume":"32","author":"M Griesshammer","year":"2006","unstructured":"Griesshammer M (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32:372\u2013380 doi: 10.1055\/s-2006-942758","journal-title":"Semin Thromb Hemost"},{"key":"531_CR104","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","volume":"131","author":"AP Wolanskyj","year":"2005","unstructured":"Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al (2005) JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 131:208\u2013213 doi: 10.1111\/j.1365-2141.2005.05764.x","journal-title":"Br J Haematol"},{"key":"531_CR105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.moh.0000208470.86732.b4","volume":"13","author":"A Tefferi","year":"2006","unstructured":"Tefferi A (2006) Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 13:93\u201398","journal-title":"Curr Opin Hematol"},{"key":"531_CR106","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","volume":"109","author":"J Kittur","year":"2007","unstructured":"Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109:2279\u20132284 doi: 10.1002\/cncr.22663","journal-title":"Cancer"},{"key":"531_CR107","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","volume":"92","author":"G Finazzi","year":"2007","unstructured":"Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92:135\u2013136 doi: 10.3324\/haematol.10634","journal-title":"Haematologica"},{"key":"531_CR108","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.exphem.2007.08.011","volume":"35","author":"HH Hsiao","year":"2007","unstructured":"Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC et al (2007) The association of JAK2(V617F) mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 35:1704\u20131707 doi: 10.1016\/j.exphem.2007.08.011","journal-title":"Exp Hematol"},{"key":"531_CR109","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313\u2013320 doi: 10.1055\/s-2007-976165","journal-title":"Semin Thromb Hemost"},{"key":"531_CR110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","volume":"81","author":"AP Wolanskyj","year":"2006","unstructured":"Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159\u2013166","journal-title":"Mayo Clin Proc"},{"key":"531_CR111","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2006-942763","volume":"32","author":"M Griesshammer","year":"2006","unstructured":"Griesshammer M, Struve S, Harrison CM (2006) Essential thrombocythemia\/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 32:422\u2013429 doi: 10.1055\/s-2006-942763","journal-title":"Semin Thromb Hemost"},{"key":"531_CR112","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.patbio.2006.06.004","volume":"55","author":"JJ Kiladjian","year":"2007","unstructured":"Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P (2007) The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Pathol Biol (Paris) 55:85\u201387 doi: 10.1016\/j.patbio.2006.06.004","journal-title":"Pathol Biol (Paris)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0531-7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T04:22:31Z","timestamp":1631506951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0531-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,16]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0531-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,16]]}}}